Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Alnylam Pharmaceuticals (NASDAQ:ALNY) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$500.9m (down 33% from 3Q 2023).
• Net loss: US$111.6m (down by 176% from US$147.8m profit in 3Q 2023).
• US$0.87 loss per share (down from US$1.18 profit in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Alnylam Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) exceeded analyst estimates by 7.7%.

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 6.4% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Alnylam Pharmaceuticals, and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.